FY2025 consolidated revenue KRW 7,536M (+9% YoY), operating loss KRW 2,433M (improved 35% from KRW 3,750M in 2024), net loss KRW 1,374M (improved 40% from KRW 2,292M)
Total assets KRW 88,259M (-24% YoY), total equity KRW 87,446M (-21% YoY), mainly due to decrease in other comprehensive income (equity securities valuation loss) and net loss
R&D expenses KRW 3,091M (41% of sales); key pipeline: diabetic foot ulcer (DFU) phase 3 in Korea and phase 2 in US, epidermolysis bullosa (EB) phase 2 in US and under review in Japan
No share buyback/cancellation or dividends; conducted a third-party allotment capital increase of KRW 5,000M (274,727 shares) in February 2025
Debt ratio 0.93% (net cash KRW 41,918M), no contingent liabilities or material lawsuits
Correction filing: removed erroneous mention of DFU Japanese approval review progress
KOSDAQ Filing Information
Filing: [Correction of Description] Business Report (2025.12)